Drug intelligence / Profile preview

sulfamethoxazole silver

Development stage: Unknown
Lead developer: Pfizer

Overview

The drug name "sulfamethoxazole silver" appears to be an incorrect or non-existent pharmaceutical name. Searches for this specific combination do not yield results for a recognized drug. It is highly probable that this name is a typo or misnomer for "silver sulfadiazine," a well-known topical sulfonamide antibiotic used for preventing and treating wound infections in burns. Sulfamethoxazole is a distinct sulfonamide antibiotic typically used systemically, often in combination with trimethoprim.

Targets

PGN (Peptidoglycan)DHPS (Dihydropteroate synthase)

Beyond the preview

Go deeper on sulfamethoxazole silver.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sulfamethoxazole silver.

Explore the full profile